Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARS-CoV-2 (COVID-19) pandemic emergency: A quick review for a quick consultation

Giovanni Paolino, Santo Raffaele Mercuri, Pietro Bearzi, Carlo Mattozzi

Research output: Contribution to journalArticlepeer-review

Abstract

The precision medicine era has helped to better manage patients with immunological and oncological diseases, improving the quality of life of this class of patients. Regarding the management of these patients and positivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), currently, limited data are available and information is evolving. In this quick review, we have analyzed the mechanisms of action and related infective risk of drugs used for the treatment of immune-mediated and oncologic skin conditions during the daily clinical practice. In general, immunosuppressant and antineoplastic agents for dermatologic treatments do not require suspension and do not require special measures, if not those commonly observed. In the case of a coronavirus disease (COVID-19) patient with complications (such as pneumonia, respiratory failure), treatment suspension should always be considered after taking into account the general condition of the patient, the risk-benefit ratio, and the pathophysiology of COVID-19 infection. The COVID-19 emergency pandemic does not imply undertreatment of existing skin conditions, which together with the SARS-CoV-2 infection may jeopardize the patient's life.

Original languageEnglish
Article numbere13537
JournalDermatologic Therapy
Volume33
Issue number5
DOIs
Publication statusPublished - Sep 1 2020

Keywords

  • biologics
  • COVID-19
  • dermatologic treatments
  • immunosuppressants
  • SARS-CoV-2
  • skin disease
  • therapy systemic

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARS-CoV-2 (COVID-19) pandemic emergency: A quick review for a quick consultation'. Together they form a unique fingerprint.

Cite this